Holen Sie sich die Stockscreener-App
8.93
6.10%
-0.58
Schlusskurs vom Vortag:
$9.51
Offen:
$9.38
24-Stunden-Volumen:
1.38M
Relative Volume:
1.20
Marktkapitalisierung:
$945.60M
Einnahmen:
$247.00M
Nettoeinkommen (Verlust:
$-249.00M
KGV:
-2.89
EPS:
-3.09
Netto-Cashflow:
$-267.00M
1W Leistung:
-1.00%
1M Leistung:
+9.84%
6M Leistung:
-42.16%
1J Leistung:
-40.19%
1-Tages-Spanne:
$8.55
$9.38
1-Wochen-Bereich:
$8.55
$9.61
52-Wochen-Spanne:
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
Firmenname
Arcus Biosciences Inc
Sektor
Branche
Telefon
(510) 694-6200
Adresse
3928 POINT EDEN WAY, HAYWARD, CA
Vergleichen Sie RCUS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
8.93 | 955.08M | 247.00M | -249.00M | -267.00M | -3.09 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-10-08 | Eingeleitet | Wells Fargo | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-24 | Eingeleitet | Berenberg | Buy |
| 2020-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2020-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-09-27 | Eingeleitet | Mizuho | Buy |
| 2019-05-24 | Fortgesetzt | Citigroup | Buy |
| 2018-10-09 | Eingeleitet | Wedbush | Outperform |
| 2018-04-09 | Eingeleitet | Citigroup | Buy |
| 2018-04-09 | Eingeleitet | Goldman | Neutral |
| 2018-04-09 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Arcus Biosciences Inc Aktie (RCUS) Neueste Nachrichten
Arcus Biosciences (NYSE:RCUS) Shares Down 8.6% – Here’s What Happened - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Arcus Biosciences’ SWOT analysis: stock’s potential in cancer therapy market By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Purchases 9,016 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Deutsche Bank AG Boosts Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: stock’s potential in cancer therapy market - Investing.com
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
Lazard Asset Management LLC Has $93,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS) - The Globe and Mail
Recent Investment Analysts’ Ratings Changes for Arcus Biosciences (RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Northern Trust Corp - Defense World
Arcus Biosciences Stock May Be The Next To Fail (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Slashed This Year's Revenue Estimates By 17% - simplywall.st
Trading (RCUS) With Integrated Risk Controls - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Sells 6,265 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Cuts Arcus Biosciences (NYSE:RCUS) Price Target to $22.00 - Defense World
First Trust Advisors LP Has $264,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Has Weak Forecast for RCUS FY2025 Earnings - Defense World
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
HC Wainwright Predicts Weaker Earnings for Arcus Biosciences - Defense World
Arcus Biosciences (RCUS): Morgan Stanley Lowers Price Target | R - GuruFocus
Wedbush Decreases Earnings Estimates for Arcus Biosciences - Defense World
Raymond James Financial Inc. Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating - marketscreener.com
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates - MSN
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) - GuruFocus
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) | RCUS Stock News - GuruFocus
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) to $26 | RCUS Stock News - GuruFocus
Arcus Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wel - GuruFocus
Arcus Biosciences (NYSE:RCUS) Shares Gap Down on Disappointing Earnings - Defense World
Analyzing Ratios: Arcus Biosciences Inc (RCUS)’s Financial Story Unveiled - DWinneX
European regulators to review Valneva shot; Jazz's stock dips on subpar first-quarter revenue - Endpoints News
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2025 Earnings Call Transcript - MSN
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wells Fargo | RCUS Stock News - GuruFocus
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Arcus Biosciences Q1 2025 Earnings Call Transcript - MarketBeat
Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo Finance
Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ... By GuruFocus - Investing.com Canada
Arcus Biosciences earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Arcus Biosciences Q1 2025 misses earnings estimates - Investing.com
Earnings call transcript: Arcus Biosciences Q1 2025 misses earnings estimates By Investing.com - Investing.com India
Arcus Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Arcus Biosciences (RCUS) Misses Q1 Revenue Expectations, Outlines Future Plans | RCUS Stock News - GuruFocus
Arcus Biosciences Q1 2025 Earnings: EPS Misses at -$1.14, Revenue Falls Short at $28 Million - GuruFocus
Arcus Biosciences Q2 2025 slides: advancing late-stage oncology pipeline with $1B cash - Investing.com Canada
Arcus Cancer Drug Shows Breakthrough 30% Response Rate in Kidney Cancer Trial, Reports Strong Q1 Earnings - Stock Titan
Earnings To Watch: Arcus Biosciences Inc (RCUS) Reports Q1 2025 Result - GuruFocus
Renaissance Technologies LLC Lowers Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Bounce 33% But Its Business Still Trails The Industry - simplywall.st
Finanzdaten der Arcus Biosciences Inc-Aktie (RCUS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):